Bluemtec Co (XKRX:439580) EBIT: ₩-987 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:439580 Bluemtec Co Ltd XKRX:439580
34 GF Score
Price ₩1,599.00
! 3 Warning Signs
View Full Analysis

What is Bluemtec Co EBIT?

Bluemtec Co XKRX:439580 -0.06% 34 EBIT is ₩-987 Mil as of Mar. 2026. GuruFocus rates XKRX:439580 with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Bluemtec Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₩-743 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₩-987 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bluemtec Co's annualized ROC % for the quarter that ended in Mar. 2026 was -2.41%. Bluemtec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -7.51%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bluemtec Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.30%.

Bluemtec Co  (XKRX:439580) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bluemtec Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-2970.944 * ( 1 - 0% )/( (119734.248 + 126409.378)/ 2 )
=-2970.944/123071.813
=-2.41 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=109964.44 - 6446.451 - ( 16280.226 - max(0, 56024.037 - 39807.778+16280.226))
=119734.248

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=113303.936 - 6370.937 - ( 19771.018 - max(0, 56985.977 - 37509.598+19771.018))
=126409.378

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Bluemtec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2970.944/( ( (39845.577 + max(-3364.59, 0)) + (39326.77 + max(-9604.456, 0)) )/ 2 )
=-2970.944/( ( 39845.577 + 39326.77 )/ 2 )
=-2970.944/39586.1735
=-7.51 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4344.202 + 12631.305 + 3013.089) - (6446.451 + 0 + 16906.735)
=-3364.59

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 11487.131 + 2878.944) - (6370.937 + 0 + 17599.594)
=-9604.456

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bluemtec Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-986.784/75807.066
=-1.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bluemtec Co EBIT Related Terms

Bluemtec Co EBIT Historical Data

* Premium members only.

The historical data trend for Bluemtec Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bluemtec Co EBIT Chart

Bluemtec Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -6,942.47 -13,022.15 -2,184.11 -2,489.22 -1,274.53

Bluemtec Co Quarterly Data
Dec20 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,030.48 -800.23 347.33 208.85 -742.74

Bluemtec Co EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Bluemtec Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bluemtec Co EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Bluemtec Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bluemtec Co's EV-to-EBIT falls into.


XKRX:439580
34GF Score
Bluemtec Co Ltd XKRX:439580
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bluemtec Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-987 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₩-987 Mil mean?
Bluemtec Co (XKRX:439580) has a EBIT of ₩-987 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bluemtec Co.
Is Bluemtec Co's EBIT too high?
Bluemtec Co's current EBIT is ₩-987 Mil. Overall, Bluemtec Co has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bluemtec Co's EBIT compare to competitors?
Bluemtec Co's EBIT of ₩-987 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Bluemtec Co. Bluemtec Co's current EBIT is ₩-987 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluemtec Co stock overvalued right now?
Bluemtec Co (XKRX:439580) has a current EBIT of ₩-987 Mil. The current EBIT is ₩-987 Mil. Bluemtec Co's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Bluemtec Co (XKRX:439580), the current EBIT is ₩-987 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bluemtec Co Business Description

Address 45 Dream Industrial Complex 1-ro, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR
Bluemtec Co Ltd is a company whose main business is selling prescription drugs through an e-commerce platform. It operates two pharmaceutical distribution platforms, BluePharmKorea targeting hospitals and clinics, and KoolPharm targeting pharmacies and provide IT services to operate and advance these two platforms. In addition, it is operating BlueLabs, which provides services and website development for pharmaceutical companies and medical institutions.
34GF Score

Get the complete analysis for XKRX:439580

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩1,599.00
Price